Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →LimmaTech Biologics AG, a Swiss clinical-stage biotech, will be acquired by Eli Lilly for next-generation vaccines against common bacterial infections.…
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals. Lilly announced agreements to acquire Curevo, LimmaTech Biologics and Vaccine…
Eli Lilly's Vaccine Acquisitions Signal a Strategy of Growth in New Areas. The three deals combined are valued at up to $3.83 billion and address viral…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly agreed to acquire Swiss bacterial-vaccine developer LimmaTech Biologics for up to $780M (cash upfront plus clinical/regulatory milestones). Lead program LTB-SA7 is in Phase 1 for Staphylococcus aureus surgical-site infection prevention; broader pipeline targets antimicrobial-resistant pathogens including Neisseria gonorrhoeae, Chlamydia trachomatis and Group B Streptococcus. Part of Lilly's three-deal infectious-disease vaccine push announced May 26.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / LimmaTech Biologics AG (this deal) | 2026 | $780M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Infectious Disease deals